Cart
sales@molnova.com
YZ9
CAS No. 6093-71-6
YZ9( —— )
Catalog No. M27745 CAS No. 6093-71-6
Y29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 μM, and acts as a competitive inhibitor against Fru-6-P with a Ki of 0.094 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameYZ9
-
NoteResearch use only, not for human use.
-
Brief DescriptionY29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 μM, and acts as a competitive inhibitor against Fru-6-P with a Ki of 0.094 μM.
-
DescriptionY29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 μM, and acts as a competitive inhibitor against Fru-6-P with a Ki of 0.094 μM.(In Vitro):Y29 inhibits the HeLa cell growth with a GI50 of 2.7 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetGlucokinase
-
RecptorNorepinephrine, 5-HT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6093-71-6
-
Formula Weight234.207
-
Molecular FormulaC12H10O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (106.75 mM)
-
SMILESCCOC(=O)c1cc2ccc(O)cc2oc1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.M I Gluckman, et al. The pharmacology of iprindole, a new antidepressant. Psychopharmacologia. 1969;15(3):169-85.
molnova catalog
related products
-
AZ6102
AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows IC50 of 5 nM for Wnt pathway inhibition in DLD-1 cells.
-
Sinogliatin
Sinogliatin (Dorzagliatin, HMS-5552, RO-5305552) is a novel, first-in-class glucokinase activator (GKS) to treat diabetes mellitus.
-
MK-0941 mesylate
MK-0941 mesylate (MK0941) is a novel potent, orally active Glucokinase (GK) activator with EC50 of 0.240 and 0.065 uM in 2.5 and 10 mM glucose, respectively.
